Santhera Taps Rare Disease Veteran as CCO to Scale AGAMREE Expansion
Event summary
- Santhera appoints Marc Clausse as Chief Commercial Officer effective June 1, 2026, succeeding Geert Jan van Daal who retires after 11 years.
- Clausse brings 25 years of rare disease and oncology commercial experience, most recently at Mirum Pharmaceuticals.
- Van Daal led European launch of AGAMREE® (vamorolone) since 2024, expanding patient access across core markets.
- AGAMREE approved in US, EU, UK, Switzerland, China, Hong Kong, and Canada with out-licensed rights in key regions.
The big picture
Santhera's CCO appointment reflects its push to scale commercial operations for AGAMREE, its lead rare disease treatment. The move comes as the company seeks to expand beyond core markets following successful European launches. Clausse's background in specialty pharma and rare diseases positions him to navigate complex international market access challenges, particularly in pricing and reimbursement. The transition also highlights Santhera's focus on sustaining growth momentum in a competitive rare disease landscape.
What we're watching
- Commercial Execution
- Whether Clausse can replicate his track record of outperforming revenue targets in Santhera's international expansion.
- Market Access
- The pace at which AGAMREE gains reimbursement approvals in new markets under Clausse's leadership.
- Portfolio Evolution
- How Santhera balances AGAMREE's growth with potential new indications or pipeline developments.
Related topics